The enzyme removes most of the antigens in Type-A and B blood and makes it into a neutral type that can be given to any patient.

"We produced a mutant enzyme that is very efficient at cutting off the sugars in A and B blood, and is much more proficient at removing the subtypes of the A-antigen that the parent enzyme struggles with," said lead author of the study David Kwan from the University of British Columbia in Canada.
To create this high-powered enzyme capable of snipping off sugars, researchers used a new technology called directed evolution that involves inserting mutations into the gene that codes for the enzyme, and selecting mutants that are more effective at cutting the antigens.
In just five generations, the enzyme became 170 times more effective.
While the researchers were able to remove the wide majority of the antigens in Type-A and B blood, before it can be used in clinical settings, the enzyme used would need to remove all of the antigens.
The immune system is highly sensitive to blood groups and even small amounts of residual antigens could trigger an immune response.
Source-Medindia
MEDINDIA




Email










